Ahead of US Biosimilar Competition for Humira, FDA to Give AbbVie's Upadacitinib Priority Review - The Center for Biosimilars

Ahead of US Biosimilar Competition for Humira, FDA to Give AbbVie's Upadacitinib Priority Review  The Center for Biosimilars

AbbVie has announced that the FDA has accepted for priority review its New Drug Application for upadacitinib for the treatment of rheumatoid arthritis (RA).



Comments

Popular posts from this blog

Epstein-Barr virus and autoimmune diseases

Chronic Lyme arthritis: A mystery solved?

Fibromyalgia — Latest Stories — Pain News Network